Skip to main content
. Author manuscript; available in PMC: 2021 Feb 17.
Published in final edited form as: Neurocrit Care. 2014 Dec;21(Suppl 2):S187–S214. doi: 10.1007/s12028-014-0039-z

Table 3.

Biomarkers for subarachnoid hemorrhage

Author/year/Ref Study design Population N Bio-marker Sample source Findings
Molecules of CNS origin
Weismann/1997/[31] Pro Aneurysmal SAH within 3 days of ictus 70 s100β Serum
  • s100β is higher at 24 h, 3 and 7 days post SAH compared to controls

  • Higher s100β levels correlate with worse HH grade.

  • higher s100β in the first week after SAH correlate with worse 6 month outcome

Stranjalis/2007/[32] Pro Spontaneous SAH within 48 h of ictus 52 s100β Serum
  • Admission s100β >0.3 μg/L predicted unfavorable outcome and is an independent predictor of short-term survival (HR 2.2) (77.8 % sensitivity; 76 % specificity)

  • s100β correlates positively with HH and Fisher scores

  • s100β decreased after EVD insertion

Oertel/2006/[33] Pro Aneurysmal SAH 51 s100β, NSE Serum
  • s100β during first 3 days of SAH is higher in those who died compared to survivors

  • all patients with s100β >1.0 μg/L had unfavorable outcome

  • NSE had no association with outcome

  • s100β is lower in patients with vasospasm (by transcranial doppler)

Coplin/1999/[34] Pro Aneurysmal SAH 27 CKBB CSF
  • CKBB >40μ/L is associated with poor outcome at hospital discharge (100 % specificity)

Inflammatory markers
Pan/2013/[65] Pro Aneurysmal SAH 262 SAH, 150 CTRL pGSN Blood
  • pGSN were lower in SAH compared with controls

  • pGSN was an independent predictor of poor functional outcome (OR = 0.957) and death (OR = 0.953) at 6 months

  • Adding pGSN improved predictive performance of WFNS and Fisher scores for functional outcome but not for mortality

Frijns/2006/[48] Pro SAH within 72 h of ictus, exclude perimesencephalic SAH 106 vWF Serum
  • vWf >94.5 nmol/L was independently associated with increased odds for poor outcome at 3 months (OR 1.1–9.8)

  • sICAM-1, sP-selectin, sE-selectin, vWf propeptide and ED 1-fibronectin were not independently associated with outcome

Mack/2002/[47] Pro SAH, excluding those with pro-inflammatory disease process 80 sICAM-1 Serum
  • sICAM-1 was elevated in SAH (293.3 ± 15 μg/L) compared with controls

  • sICAM-1 on post-SAH days 8, 10, and 12 were significantly elevated in those with unfavorable mRS at discharge

Beeftink/2011/[46] Pro Aneurysmal SAH 67 TNFα, Leukocytes, CRP Serum
  • Neither TNFα nor TNF-α genotype were associated with DCI or with SAH outcome at 3 months

  • High leukocyte count and high CRP are not associated with DCI or SAH outcome

Chou/2011/[38] Pro Spontaneous SAH, within 96 h of ictus 55 MMP-9 CSF
  • Elevation of MMP-9 on post-SAH days 2–3 is associated with poor outcome (mRS 3–6) at 3 months

Chou/2011/[38] Pro Spontaneous SAH, within 96 h of ictus 55 Neutrophil, WBC Blood
  • Elevated neutrophil count on post-SAH day 3 is associated with poor 3-month outcome

  • Elevated WBC count throughout post-SAH days 0–14 is associated with angiographic vasospasm

Chou/2012/[50] Pro Spontaneous SAH, within 96 h of ictus 52 TNFα, IL-6 Serum
  • Elevated TNFα over post-SAH days 0–14 is independently associated with poor long-term outcome

  • IL-6 is not associated with SAH outcome

  • Neither TNFα nor IL-6 was associated with angiographic vasospasm

Chou/2011/[64] Pro Spontaneous SAH, within 96 h of ictus 42 pGSN CSF, Serum
  • Serum pGSN is decreased in SAH compared to controls and decreases over time in SAH

  • CSF pGSN is decreased in SAH compared to controls.

  • Novel pGSN fragments found in SAH CSF but not in controls

Fassbender/2001/[52] Pro Aneurysmal SAH within 48 h of ictus 35 IL-1β, IL-6, TNFα CSF, Serum
  • IL-lβ and IL-6 are significantly higher in CSF than in serum in SAH

  • CSF IL-6 on post-SAH day 5 is significantly elevated in poor outcome group

  • CSF TNFα did not show significant association with outcome

Mathiesen/1997/[53] Pro SAH patients with EVD 22 IL-1Rα, TNFα CSF
  • IL-IRα was higher in poor grade SAH (HH 3–4; 318 vs. 82 pg/mL)

  • Elevated IL-IRα and TNFα on post-SAH days 4–10 were associated with poor outcome

Weir/1989/[43] Retro Aneurysmal SAH with vital signs and CBC data (76 % missing data) 173 WBC Blood
  • admission WBC >15 × 109/L shows 55 % mortality vs. 25 % mortality in the lower WBC group

Niikawa/1997/[39] Retro Fisher grade 3 SAH treated with aneurysm clipping within 24 h of ictus 103 WBC Blood
  • WBC counts during days 3–5, 6–8, 9–11, and 12–14 after onset of SAH were significantly higher in patients with than in patients without symptomatic vasospasm

Other biomarkers
Niskakangas/2001/[79] Case control Aneurysmal SAH 108 ApoE4 Blood
  • Presence of ApoE4 was associated with unfavorable outcome (OR = 2.8 [1.18–6.77])

Juvela/2009/[76] Case control SAH within 48 h of ictus 105 ε2, ε4–containing genotypes Blood
  • Apolipoprotein E ε2 or ε4-containing genotypes were not associated with outcome or occurrence of cerebral infarction

Lanterna/2005/[78] Case control SAH HH grade 1–3 101 ApoE4 genotype Blood
  • Presence of Apo E4 genotype is associated with negative overall outcome

  • Apo E4 genotype is associated with development of DIND

Leung/2002/[77] Case control Spontaneous SAH 72 ApoE4 genotype Blood
  • ApoE4 genotype is associated with poor 6-month outcome (OR = 11.3 [2.2–57.0])

Kay/2003/[81] Case Control Spontaneous SAH requiring EVD 19 s100β, ApoE CSF
  • s100β is significantly higher in SAH compared to controls

  • ApoE is significantly lower in SAH compared to controls.

  • Lower ApoE was associated with better clinical outcome

Lanterna/2005/[78] Meta-analysis Consecutive SAH, with 3-month follow-up data 696 ApoE4 genotype Blood
  • Apo E4 genotype is associated with negative outcome (OR = 2.558 [1.610–4.065]) and delayed ischemia (OR 2.044 [1.269–3.291])

Moussouttas/2012/[88] Pro SAH with EVD, HH grade 3–5, endovascular aneurysm treatment 102 Epinephrine CSF
  • Elevated CSF epinephrine within 48 h of admission is independently associated with mortality at 15 days (OR = 1.06 [1.01–1.10]) and with death and disability at 30 days (OR = 1.05 [1.02–1.09])

Yarlagadda/2006/[84] Pro Spontaneous SAH, >21 years 300 BNP, cTI Serum
  • Initial BNP >600 pg/mL is associated with death (OR = 37.7 [5.0–286.2])

  • cTI >0.3 mg/L (on post-SAH day 9 ± 4) is associated with death (OR = 4.9 [2.1–26.8])

  • No standardized time of biosample collection

Naidech/2005/[82] Pro Spontaneous non-traumatic SAH 253 cTI Serum
  • Peak cTI was independently predictive of death or severe disability at hospital discharge (OR = 1.4 [1.1–1.9])

  • cTI not independently predictive of 3-month outcome by mRS

Ramappa/2008/[83] Retro SAH diagnosed by CT scan or CSF, SAH ICD-9 code, with cTI measured 83 cTI Blood
  • Peak cTI and GCS on presentation independently predicted in-hospital mortality

Pro prospective observational, Retro retrospective, CTRL control subjects, CBC complete blood count, HH grade hunt and hess grade, WFNS World Federation of Neurosurgeons Classification, DIND delayed ischemic neurological deficit, DCI delayed cerebral ischemia, mRS modified Rankins score, OR odds ratio